CD274 and breast carcinoma: These findings suggest that while immune checkpoint inhibitors like pembrolizumab have demonstrated clinical benefits in various subtypes of breast cancer, the identification of predictive biomarkers such as PD-L1 expression and TMB is crucial for optimizing treatment selection.